Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 681.78

+1.0%

Nov 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2782)	11/7/2019 11:49:28 AM
From: Miljenko Zuanic	of 3557

RE: anti-CTLA4 IO contribution to 1L NSCLC, is there any space left? Early enthusiasm disapeared as data from trials start to role in: ncbi.nlm.nih.gov and, there is additional concern... ncbi.nlm.nih.gov Severe toxicity pushed toward regime where Ipi is taight controled...still, data were short of expectation. Now, investigator (even with latest bit positive outcome) are rolling out anti-CTLA4 arm. for instance, in cemiplimab second 1L NSCLC ( clinicaltrials.gov ), ipi arm was not included in part-2 (randomized part) of the chemo-combination. In all, without good biomarker(s) that can predict benefit of the aCTLA4, due to severe toxicity and in same cases worse outcome...it may slowly disappear as option. BMY is looking at triple IO regime (214 + nivo + Ipi), including NSCLC (in addition to RCC, melanoma and UC), MRK is still silent on their aCTLA4 regime/molecule.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next